Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 63 results for glaucoma

  1. Glaucoma - lerdelimumab (CAT-152) [ID383]

    In development [GID-TAG381] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA671

  3. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

    Medtech innovation briefing
    Published
    18 January 2017

  4. Ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma (IPG605)

    October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.

    Interventional procedures guidance
    Published
    28 February 2018

  5. Long-term effectiveness of selective laser trabeculoplasty: What is the long-term effectiveness and cost effectiveness of selective laser trabeculoplasty as a first-line treatment compared with intraocular pressure-lowering eye drops in ocular hypertension or COAG in adults?

    applicable) Source guidance details Comes from guidance Glaucoma: diagnosis and management Number NG81 Date issued

    Research recommendation
    Published
    1 February 2022

  6. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.

    Technology appraisal guidance
    Published
    26 March 2008
    View recommendations

    Sections for TA138

  7. Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium (IPG216)

    Evidence-based recommendations on tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium. This involves taking limbal stem cells from a living or deceased donor, growing them in the laboratory and transplanting them onto the patient’s affected eye(s).

    Interventional procedures guidance
    Published
    25 April 2007
    View recommendations

    Sections for IPG216

  8. Intraocular lens insertion for correction of refractive error, with preservation of the natural lens (IPG289)

    Evidence-based recommendations on intraocular lens insertion for correction of refractive error, with preservation of the natural lens. This involves inserting an artificial lens inserted into the eye through a small cut made in the cornea.

    Interventional procedures guidance
    Published
    25 February 2009
    View recommendations

    Sections for IPG289

  9. Photorefractive (laser) surgery for the correction of refractive errors (IPG164)

    Evidence-based recommendations on photorefractive (laser) surgery for the correction of refractive errors. This involves using a special laser to permanently change the shape of the cornea.

    Interventional procedures guidance
    Published
    22 March 2006
    View recommendations

    Sections for IPG164

  10. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development [GID-TA11146] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Arteriovenous crossing sheathotomy for branch retinal vein occlusion (IPG334)

    Evidence-based recommendations on arteriovenous crossing sheathotomy for branch retinal vein occlusion. This involves cutting the sheath around the vessels and physically separating them where they cross to improve blood flow through the vein.

    Interventional procedures guidance
    Published
    24 March 2010
    View recommendations

    Sections for IPG334

  12. Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

    Interventional procedures guidance
    Published
    23 March 2011
    View recommendations

    Sections for IPG385

  13. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 March 2017

  14. Interventional procedures advisory committee members

    Interventional Procedures Advisory Committee members

  15. Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in children under 12.

    Technology appraisal guidance
    Published
    28 November 2007
    View recommendations

    Sections for TA131